论文部分内容阅读
目的探讨瑞舒伐他汀治疗老年脑梗死患者颈动脉中重度狭窄的疗效。方法老年脑梗死患者80例,根据随机数字表法将患者分为瑞舒伐他汀组和对照组,各40例。对照组采用常规治疗方法。瑞舒伐他汀组在对照组基础上加用瑞舒伐他汀。两组连续治疗6个月。比较两组治疗前后的颈动脉内膜中层厚度(IMT)、斑块面积、血脂指标及美国国立卫生研究院卒中量表(NIHSS)评分变化情况。对比两组的临床疗效。结果治疗后,瑞舒伐他汀组血脂指标[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)]和IMT的降低程度明显低于对照组(P<0.05)。治疗后瑞舒伐他汀组的NIHSS评分和斑块面积明显低于对照组(P<0.05);瑞舒伐他汀组治疗总有效率为80.0%,明显高于对照组的52.5%,差异有统计学意义(P<0.05)。结论瑞舒伐他汀具有调理血脂、抑制炎症反应、减少血小板凝聚,改善微循环的作用。
Objective To investigate the efficacy of rosuvastatin in the treatment of moderate-severe carotid stenosis in elderly patients with cerebral infarction. Methods Eighty elderly patients with cerebral infarction were divided into rosuvastatin group and control group according to random number table method, 40 cases in each group. Control group using conventional treatment. Rosuvastatin group on the basis of the control group with rosuvastatin. Two groups of continuous treatment for 6 months. The changes of carotid intima-media thickness (IMT), plaque area, blood lipid and NIHSS score before and after treatment were compared between the two groups. Compare the clinical efficacy of the two groups. Results After treatment, the reduction of serum lipids (total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C)] and IMT in rosuvastatin group was significantly lower than that in the control group ). After treatment, the NIHSS score and plaque area in rosuvastatin group were significantly lower than those in control group (P <0.05). The total effective rate in rosuvastatin group was 80.0%, which was significantly higher than that in control group (52.5%) Significance (P <0.05). Conclusion Rosuvastatin can regulate blood lipids, inhibit inflammatory reaction, reduce platelet aggregation and improve microcirculation.